



GODAVARI DRUGS LIMITED

Regd. Off.: 'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.
Voice : +91-40-2784 9700 / 2784 2602 / 2784 4557
E-mail : info@godavaridrugs.com | Website : www.godavaridrugs.com

Date: 12.11.2022

To,
The General Manager,
Listing Department,
Bombay Stock Exchange
1st Floor, New trading Wing,
Rotunda Building, P.J. Towers,
Dalal Street Fort,
Mumbai-400001

Dear Sir/Madam,

Sub: Financial Results for quarter ended September, 2022-Regulation 33

With reference to the subject cited, it is hereby informed that the Board of Directors of the Company at its meeting through Video Conferencing held on Saturday, 12th November, 2022 at 11:30 A.M, interalia considered and approved the unaudited Financial Results for the quarter & half year ended September, 2022

Copy of Unaudited Financial Results for the quarter & half year ended September, 2022 is enclosed herewith

Kindly take the same on record and acknowledge the receipt of same.

Thanking You
For Godavari Drugs Limited

Rashmi Agarwal
Company Secretary & Compliance Officer



**Auditor's Report on Standalone Quarterly and Half Yearly Unaudited Financial Results of
Godavari Drugs Limited, Secunderabad, Telangana, pursuant to Regulation 33 of SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015.**


To,
The Board of Directors
Godavari Drugs Limited
Secunderabad.

We have reviewed the accompanying statement of unaudited standalone financial results of Godavari Drugs Limited for the second quarter and half year ended 30th September, 2022. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ayyadevara & Co.,
Chartered Accountants
FRN: 000278S


Ayyadevara Srinivas
Proprietor

ICAI Membership No. 028803
12/11/2022 : Hyderabad
UDIN: 22028803BCXEQD2390



GODAVARI DRUGS LIMITED

CIN NO.L24230TG1987PLC008016

Regd. Office : - "Mayfair", S.P.Road, Secunderabad.

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2022


(Rs. In Lakhs)

Sl. N o.	Particulars	Quarter ended			Half Year Ended		Year ended
		30.09.2022	30.06.2022	30.09.2021	30.09.2022	30.09.2021	31.03.2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	4054.71	4255.00	3866.67	8309.71	8306.85	16110.62
2	Other Income	13.20	6.68	9.05	19.88	10.75	27.63
3	Total Revenue from operations (1+2)	4067.91	4261.68	3875.72	8329.59	8317.60	16138.25
4	Expenses						
	(a) Cost of materials consumed	3662.06	3889.63	3290.26	7551.69	6953.36	12797.36
	(b) Changes in inventories of finished goods & work-in-progress	-371.12	-467.12	-197.50	-838.24	-285.25	248.19
	(c) Employee benefits expense	113.93	116.78	132.29	230.71	250.43	495.65
	(d) Depreciation & amortization expense	47.25	46.10	42.53	93.35	84.28	169.64
	(e) Finance Costs	105.69	74.18	78.52	179.87	149.78	284.93
	(f) Other Expenses	393.06	475.56	351.26	868.62	788.33	1440.43
	Total expenses	3950.89	4135.13	3697.36	8086.02	7940.93	15436.20
5	Profit before exceptional Items and tax (3-4)	117.02	126.55	178.36	243.57	376.67	702.06
6	Exceptional items						
7	Profit before Tax (5-6)	117.02	126.55	178.36	243.57	376.67	702.06
8	Tax expense	-30.63	-34.40	-56.23	-65.03	-112.11	-177.53
9	Net Profit for the period (7-8)	86.39	92.15	122.13	178.54	264.56	524.53
10	Other Comprehensive Income						
	Items that will not be reclassified to profit or loss						
(i)	loss						
	Income tax relating to Items that will not be reclassified to profit or loss						
(ii)							
	Items that will be reclassified to profit or loss						
(iii)	Income tax relating to Items that will be reclassified to profit or loss						
(iv)							
11	Total Comprehensive Income (9+10)	86.39	92.15	122.13	178.54	264.56	524.53
12	Paid-up equity share capital (Face Value Rs. 10/- per share)	753.05	753.05	753.05	753.05	753.05	753.05
13	Other Equity(Reserves and Surplus)						2210.09
14	Earnings per share (of Rs.10/- each) (not annualized)						
	(a) Basic	1.15	1.22	1.62	2.37	3.51	6.97
	(b) Diluted	1.15	1.22	1.62	2.37	3.51	6.97


Notes:

- The above results, as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at its meeting held on 12th November 2022.
- The above results were prepared in accordance with Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable
- The Limited Review by the Statutory Auditors for the quarter ended as required under regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been received.
- Corresponding figures in previous year / period have been regrouped wherever considered necessary.

For GODAVARI DRUGS LIMITED



Mohit Jaju
CFO
DIN: 03405414



Plac Secunderabad
Date 12-11-2022

GODAVARI DRUGS LIMITED
CIN NO.L24230TG1987PLC008016
Regd. Office : - "Mayfair", S.P.Road, Secunderabad.


Statement of Assets and Liabilities

(Rs. In Lakhs)

Particulars	Quarter ended (30.09.2022) (Unaudited)	Year ended (31.03.2022) (Audited)
ASSETS		
1. Non - current assets		
a. Property, plant and equipment	2600.52	2625.11
b. Capital work - in -progress	447.16	49.00
c. Investment Property		
d. Goodwill		
e. Other Intangible assets		
f. Intangible assets under development		
g. Biological Assets other than bearer plants		
h. Financial Assets		
(i) Investments	0.01	0.01
(ii) Trade Receivables		
(iii) Loans		
(iv) Other Financial Assets	44.05	33.56
i. Deferred tax assets (net)		
j. Other non-current assets		
2. Current assets		
(a) Inventories	2482.36	1003.37
(b) Financial Assets		
(i) Investments		
(ii) Trade Receivables	5982.49	5557.90
(iii) Cash and cash equivalents	301.28	227.64
(iv) Bank balances other than (iii) above		
(v) Loans	87.22	60.87
(vi) Others (to be specified)		
(c) Current Tax Assets (Net)		
(d) Other current assets	435.07	583.64
Total Assets	12380.16	10141.10
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity Share capital	753.05	753.05
(b) Other Equity	2388.63	2210.09
(i) Reserves and surplus		
Non controlling interest		
LIABILITIES		
1. Non - current liabilities		
(a) Financial Liabilities		
(i) Borrowings	1113.30	1178.21
(ii) Trade payables		
(iii) Other financial liabilities (other than those specified in item (b))		
(b) Provisions	70.96	72.27
(c) Deferred tax liabilities (Net)	164.08	151.36
(d) Other non-current liabilities		
2. Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	2181.66	856.12
(ii) Trade payables		
(A) Total outstanding dues of micro enterprise and small enterprise and	1.44	13.90
(B) Total outstanding dues creditors other than of micro enterprise and small enterprise	5173.60	4317.79
(iii) Other financial liabilities (other than those specified in item (c))	438.27	433.72
(b) Other current liabilities	42.85	31.89
(c) Provisions		
(d) Current Tax Liabilities (Net)	52.31	122.68
Total Equity and Liabilities	12380.16	10141.10

For GODAVARI DRUGS LIMITED

Mohit Jais
CFO
DIN: 03405414



Place: Secunderabad
Date : 12.11.2022

Godavari Drugs Limited
Cash Flow Statement for the Quarter ended September 30,2022.

Rupees In Lakhs

Particulars	Period ended 30.09.2022	Previous Year 2021-22
A. Cash Flow from Operating Activities		
Profit before Depreciation, Interest and Tax	516.80	1,156.63
Other income considered separately	(19.88)	(27.63)
Net	496.92	1,129.00
(Increase) / Decrease in Inventories	(1,478.99)	461.63
(Increase) / Decrease in Receivables	(424.59)	(1,045.79)
(Increase) / Decrease in Short term Loans & Advances	(26.35)	(4.14)
(Increase) / Decrease in Other Current Assets	148.57	(19.97)
Increase / (Decrease) in Current Liabilities	2,133.86	779.77
Less: Income tax paid	(58.13)	(122.68)
Less: Deferred Tax Adjustment	(14.04)	(54.85)
Total A	777.25	1,122.98
B. Cash Flow from Investing Activities		
Increase in Fixed Assets and Capital WIP	(466.92)	(524.51)
Increase in Non Current Assets	(10.48)	(0.18)
Other Income	19.88	27.63
Total B	(457.52)	(497.07)
C. Cash Flow from Financing Activities		
Increase / (Decrease) in Long Term Borrowings	(64.90)	(270.77)
Increase / (Decrease) in Long Term Provisions	(1.31)	(6.41)
Increase / (Decrease) in Long Term Advances		
Interest Paid	(179.87)	(284.93)
Total C	(246.09)	(562.10)
D. Net Increase/(Decrease) in cash and cash equivalents [A+B+C]	73.64	63.81
Cash and cash equivalents at the beginning of the year (01.04.2022)	227.64	163.83
Cash and cash equivalents at the end of the year (30.09.2022)	301.28	227.64
Increase/(-)Decrease	73.64	63.81

Place: Secunderabad

Date : 12.11.2022

For GODAVARI DRUGS LIMITED


Mohit Jaju

CFO

DIN: 03405414

